Targeting Chondroitin Sulfate Proteoglycans: An Emerging Therapeutic Strategy to Treat CNS Injury

ACS Chem Neurosci. 2020 Feb 5;11(3):231-232. doi: 10.1021/acschemneuro.0c00004. Epub 2020 Jan 15.

Abstract

Chondroitin sulfate proteoglycans (CSPGs) are the most abundant components of glial scar formed after severe traumatic brain injury as well as spinal cord injury and play a crucial inhibitory role in axonal regeneration by selective contraction of filopodia of the growth cone of sprouting neurites. Healing of central nervous system (CNS) injury requires degradation of the glycosamine glycan backbone of CSPGs in order to reduce the inhibitory effect of the CSPG layer. The key focus of this Viewpoint is to address a few important regenerative approaches useful for overcoming the inhibitory barrier caused by chondroitin sulfate proteoglycans.

Keywords: Central nervous system injury; axonal regeneration; chondroitin sulfate proteoglycan; chondroitinase ABC enzyme; glial scar; heparan sulfate proteoglycan.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Central Nervous System / drug effects*
  • Central Nervous System / metabolism*
  • Chondroitin Sulfate Proteoglycans / metabolism*
  • Chondroitin Sulfate Proteoglycans / pharmacology*
  • Humans
  • Nerve Regeneration / drug effects
  • Neurites / drug effects
  • Neurites / metabolism
  • Pseudopodia / drug effects
  • Pseudopodia / metabolism
  • Spinal Cord Injuries / drug therapy*
  • Spinal Cord Injuries / metabolism

Substances

  • Chondroitin Sulfate Proteoglycans